Chloramphenicol and rifampin may be the only options against Stenotrophomonas maltophilia. A tale of a colonized bladder device in a patient with myelofibrosis

Infezioni in Medicina

Volumn 18, Issue 3, 2010, Pages 193-197

  Savini, Vincenzo ^a   Catavitello, Chiara ^a   D'Aloisio, Marianna ^a   Balbinot, Andrea ^a   Astolfi, Daniela ^a   Masciarelli, Gioviana ^a   Pompilio, Arianna ^b   Di Bonaventura, Giovanni ^b   D'Antonio, Domenico ^a  

^a SPIRITO SANTO HOSPITAL   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; SULTAMICILLIN; TETRACYCLINE; TIGECYCLINE; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; BACTERIAL COLONIZATION; BACTERIURIA; BLADDER CATHETERIZATION; DEVICE; LETTER; MULTIDRUG RESISTANCE; MYELOFIBROSIS; STENOTROPHOMONAS MALTOPHILIA;

ANTI-BACTERIAL AGENTS; BACTERIURIA; BIOFILMS; CATHETER-RELATED INFECTIONS; CHLORAMPHENICOL; DISEASE SUSCEPTIBILITY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; EQUIPMENT CONTAMINATION; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; PRIMARY MYELOFIBROSIS; RIFAMPIN; STENOTROPHOMONAS MALTOPHILIA; URINARY CATHETERIZATION; URINARY RETENTION;

EID: 78049479089     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (20)

1. Safdar A., Rolston K.V. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin. Infect. Dis. 23 (12), 1602-1609, 2007. (Pubitemid 351411846)
2. Alonso A., Martínez J.L. Cloning and characterization of SmeDEF, a novel multidrug efflux pump from Stenotrophomonas maltophilia. Antimicrob. Agents. Chemother. 44 (11), 3079-3086, 2000. (Pubitemid 35192901)
3. Yemisen M., Mete B., Tunali Y., et al. A meningitis case due to Stenotrophomonas maltophilia and review of the literature. Int. J. Infect. Dis.12 (6), e125-127, 2008.
4. Falagas M.E., Valkimadi P.E., Huang Y.T., et al. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J. Antimicrob. Chemother. 62 (5), 889-894, 2008.
5. Falagas M.E., Kastoris A.C., Vouloumanou E.K., et al. Community-acquired Stenotrophomonas maltophilia infections: a systematic review. Eur. J. Clin. Microbiol. Infect. Dis. 28 (7), 719-730, 2009.
6. Sanchez M.B., Hernandez A., Martinez J.L. Stenotrophomonas maltophilia drug resistance. Future Microbiol. 4, 655-660, 2009.
7. th informational supplement. 2003. Approved standard M2-A7. National Committee for Clinical Laboratory Standards, Wayne, Pa.
8. Alonso A., Martinez J.L. Expression of multidrug efflux pump SmeDEF by clinical isolates of Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 45 (6), 1879-1881, 2001.
9. Pompilio A., Catavitello C., Picciani C., et al. Subinhibitory concentrations of moxifloxacin decrease adhesion and biofilm formation of Stenotrophomonas maltophilia from cystic fibrosis. J. Med. Microbiol. 59 (Pt 1), 76-81, 2010.
10. Pompilio A., Piccolomini R., Picciani C., et al. Factors associated with adherence to and biofilm formation on polystyrene by Stenotrophomonas maltophilia: the role of cell surface hydrophobicity and motility. FEMS Microbiol. Lett. 287 (1), 41-47, 2008.
11. Di Bonaventura G., Prosseda G., Del Chierico F., et al. Molecular characterization of virulence determinants of Stenotrophomonas maltophilia strains isolated from patients affected by cystic fibrosis. Int. J. Immunopathol. Pharmacol. 20 (3), 529-537, 2007.
12. Di Bonaventura G., Spedicato I., D'Antonio D. et al. Biofilm formation by Stenotrophomonas maltophilia: modulation by quinolones, trimethoprim- sulfamethoxazole, and ceftazidime. Antimicrob. Agents Chemother. 48 (1), 151-160, 2004. (Pubitemid 38040191)
13. Di Bonaventura G., Stepanovi S., Picciani C., et al. Effect of environmental factors on biofilm formation by clinical Stenotrophomonas maltophilia isolates. Folia Microbiol. (Praha) 52 (1), 86-90, 2007. (Pubitemid 46631954)
14. Traub W.H., Leonhard B., Bauer D. Stenotrophomonas (Xanthomonas) maltophilia: in vitro susceptibility to selected antimicrobial drugs, single and combined, with and without defibrinated human blood. Chemotherapy 44 (5), 293-304, 1998. (Pubitemid 28386662)
15. Das T., Deshmukh H.S., Mathai A., et al. Stenotrophomonas maltophilia endogenous endophthalmitis: clinical presentation, sensitivity spectrum and management. J. Med. Microbiol. 58 (Pt 6), 837-838, 2009.
16. Horster S., Bader L., Seybold U., et al. Stenotrophomonas maltophilia induced post-cataractsurgery endophthalmitis: outbreak investigation and clinical courses of 26 patients. Infection. 37 (2), 117-122, 2009.
17. Friedman N.D., Korman T.M., Fairley C.K., et al. Bacteraemia due to Stenotrophomonas maltophilia: an analysis of 45 episodes. J. Infect. 45 (1), 47-53, 2002.
18. Mehta N.J, Khan I.A., Mehta R.N., et al. Stenotrophomonas maltophilia endocarditis of prosthetic aortic valve: report of a case and review of literature. Heart Lung 29 (5), 351-355, 2000.
19. Zhang L., Li X.Z., Poole K. Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system. Antimicrob. Agents Chemother. 44 (2), 287-293, 2000.
20. Alonso A., Martínez J.L. Multiple antibiotic resistance in Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 41 (5), 1140-1142, 1997.